NCT06710756 - Lead-212 PSV359 Therapy for Patients With Solid Tumors | Biotech Hunter

Enrollment

112

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

May 28, 2032

Conditions

Pancreatic Ductal AdenocarcinomaGastric CancerEsophageal CancerColorectal CancerOvarian CancerHead and Neck CancerSarcomaMesothelioma

Interventions

DRUG

[203Pb]Pb-PSV359

\[203Pb\]Pb-PSV359 is administered by intravenous bolus injection for single-photon emission computed tomography imaging.

DRUG

[212Pb]Pb-PSV359

\[212Pb\]Pb-PSV359 is administered by intravenous infusion for treatment of FAP expressing cancers.

Trial Locations (2)

RECRUITING

Saint Louis University, St Louis

RECRUITING

Nebraska Cancer Specialists, Omaha